In addition, this paper suggested a hypothetical model where IL-1β stimulation activates the NF-κB pathway and induces PKCι-mediated phosphorylation of PRMT5, opening-up novel therapeutic avenues for CRC patients based on disrupting the PKCι/PRMT5/NF-κB and RIOK1 signaling axis [48]. This evidence concerns the gene NFKB1 and colorectal carcinoma.